erlotinib hydrochloride has been researched along with Chemical and Drug Induced Liver Injury in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 15 (78.95) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hayashi, R; Inomata, M; Kambara, K; Kashii, T; Konishi, H; Miwa, T; Okazawa, S; Shimokawa, K; Tanaka, H; Tobe, K; Tokui, K; Yamada, T | 1 |
| Baba, T; Ikeda, S; Iwasawa, T; Kato, T; Ogura, T; Okudela, K; Sekine, A; Yamakawa, H; Yamanaka, Y | 1 |
| Chen, X; Li, S; Peng, Y; Yang, Z; Zhao, H; Zheng, J | 1 |
| Hsu, WH; Loong, HH; Mok, TS; Yang, JC | 1 |
| Chen, L; Huang, Y; Liu, J; Ma, Y; Wu, H; Zhao, H; Zhou, N | 1 |
| Fukuoka, M; Hasegawa, Y; Ozaki, T; Sugiura, T; Suzumura, T; Tsukuda, H; Yonesaka, K | 1 |
| Iseri, K; Iyoda, M; Kuno, Y; Matsumoto, K; Saito, T; Shibata, T; Shindo-Hirai, Y; Suzuki, T; Wada, Y; Yamamoto, Y | 1 |
| Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Hayashi, H; Kudo, K; Nakagawa, K; Takeda, M; Ueda, H | 1 |
| Fimognari, FL; Franco, A; Pastorelli, R; Pellegrinotti, M; Repetto, L | 1 |
| Fukuoka, M; Nakagawa, K; Okamoto, I; Takeda, M | 1 |
| Ishikawa, H; Kato, T; Naito, T; Nakagaki, S; Ohashi, Y; Onishi, T; Sakurai, M; Shino, M; Suzuki, K; Takahashi, T; Yamamoto, N | 1 |
| Azuma, J; Fujio, Y; Furukawa, M; Goya, S; Hirata, H; Kawase, I; Kida, H; Kijima, T; Minami, T; Nagatomo, I; Nonen, S; Otani, Y; Shimizu, T; Tachibana, I; Takahashi, R; Takeda, Y | 1 |
| Chang, SC; Hsu, SY; Kuo, LC; Lai, JI; Lai, YC; Lin, PC; Wang, WS | 1 |
| Ishida, T; Iwasaku, M; Korogi, Y; Kunimasa, K; Masuda, G; Nishiyama, A; Takaiwa, T; Yoshioka, H | 1 |
| Hokkoku, K; Igarashi, S; Kitade, H; Mori, M; Nakai, M; Sagawa, M; Shintaku, K; Yamada, T; Yano, S | 1 |
| Ramanarayanan, J; Scarpace, SL | 1 |
| Saif, MW | 1 |
| Krishnan, GS; Ramanarayanan, J | 1 |
4 review(s) available for erlotinib hydrochloride and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
Overview of current systemic management of EGFR-mutant NSCLC.
Topics: Acneiform Eruptions; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Diarrhea; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Exons; Humans; Lung Diseases, Interstitial; Lung Neoplasms; Molecular Targeted Therapy; Mucositis; Paronychia; Patient Selection; Progression-Free Survival; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic | 2018 |
Pooled safety analysis of EGFR-TKI treatment for EGFR mutation-positive non-small cell lung cancer.
Topics: Afatinib; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Quinazolines | 2015 |
Erlotinib-induced acute hepatitis in a patient with pancreatic cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme System; Deoxycytidine; ErbB Receptors; Erlotinib Hydrochloride; Gemcitabine; Humans; Liver; Male; Middle Aged; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Review: hepatotoxicity and EGFR inhibition.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; ErbB Receptors; Erlotinib Hydrochloride; Humans; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
15 other study(ies) available for erlotinib hydrochloride and Chemical and Drug Induced Liver Injury
| Article | Year |
|---|---|
[A Case of Lung Adenocarcinoma Presenting with Leptomeningeal Carcinomatosis Successfully Treated with Afatinib after Erlotinib-Induced Hepatotoxicity].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Male; Meningeal Carcinomatosis; Quinazolines; Treatment Outcome | 2017 |
Afatinib Therapy for Brain Metastases Aggravated by a Reduction in the Dose of Erlotinib Due to the Development of Hepatotoxicity.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged, 80 and over; Brain Neoplasms; Chemical and Drug Induced Liver Injury; Dose-Response Relationship, Drug; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Lung Neoplasms; Quinazolines | 2017 |
Identification of Ketene-Reactive Intermediate of Erlotinib Possibly Responsible for Inactivation of P450 Enzymes.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Erlotinib Hydrochloride; Ethylenes; Heme; Humans; Ketones; Microsomes, Liver; Protein Binding | 2018 |
[The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Cost-Benefit Analysis; Diarrhea; ErbB Receptors; Erlotinib Hydrochloride; Exanthema; Female; Follow-Up Studies; Gefitinib; Humans; Insurance, Health; Kaplan-Meier Estimate; Lung Neoplasms; Male; Middle Aged; Mutation; Patient Outcome Assessment; Protein Kinase Inhibitors; Quinazolines | 2013 |
Erlotinib is a well-tolerated alternate treatment for non-small cell lung cancer in cases of gefitinib-induced hepatotoxicity.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Drug Substitution; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2014 |
Epidermal growth factor receptor inhibition with erlotinib partially prevents cisplatin-induced nephrotoxicity in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Body Weight; Cell Line; Chemical and Drug Induced Liver Injury; Cisplatin; ErbB Receptors; Erlotinib Hydrochloride; Humans; Kidney Tubules, Proximal; Liver; Macrophages; Male; Phosphorylation; Protein Kinase Inhibitors; Quinazolines; Rats; Rats, Sprague-Dawley; RNA, Messenger | 2014 |
Successful treatment with afatinib after gefitinib- and erlotinib-induced hepatotoxicity.
Topics: Adenocarcinoma; Afatinib; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Prognosis; Quinazolines; Radiation-Sensitizing Agents | 2016 |
Erlotinib-induced hepatitis complicated by fatal lactic acidosis in an elderly man with lung cancer.
Topics: Acidosis, Lactic; Adenocarcinoma; Aged; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; Diabetes Mellitus; Erlotinib Hydrochloride; Fatal Outcome; Humans; Lung Neoplasms; Male; Metformin; Quinazolines | 2009 |
Successful treatment with erlotinib after gefitinib-related severe hepatotoxicity.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Quinazolines | 2010 |
[Safety analysis of eight patients treated with erlotinib after severe gefitinib-induced liver injury].
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Enzyme Inhibitors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Molecular Structure; Quinazolines | 2010 |
Safe and successful treatment with erlotinib after gefitinib-induced hepatotoxicity: difference in metabolism as a possible mechanism.
Topics: Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Japan; Liver; Lung Neoplasms; Mutation; Quinazolines; Transaminases; Treatment Outcome | 2011 |
Successful treatment of erlotinib-induced acute hepatitis and acute interstitial pneumonitis with high-dose corticosteroid: a case report and literature review.
Topics: Adenocarcinoma; Adrenal Cortex Hormones; Aged; Alanine Transaminase; Anti-Inflammatory Agents; Antineoplastic Agents; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Humans; Liver Function Tests; Lung Diseases, Interstitial; Lung Neoplasms; Male; Methylprednisolone; Muscle Weakness; Quinazolines; Radiography, Thoracic | 2011 |
Successful treatment of non-small cell lung cancer with gefitinib after severe erlotinib-related hepatotoxicity.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Chemical and Drug Induced Liver Injury; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Middle Aged; Protein Kinase Inhibitors; Quinazolines; Treatment Outcome | 2012 |
[Efficacy of low-dose erlotinib against gefitinib-induced hepatotoxicity in a patient with lung adenocarcinoma harboring EGFR mutations].
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Aged, 80 and over; Antineoplastic Agents; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines | 2013 |
Acute drug induced hepatitis due to erlotinib.
Topics: Adenocarcinoma; Aged; Alanine Transaminase; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; ErbB Receptors; Erlotinib Hydrochloride; Humans; Male; Pancreatic Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2007 |